## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `ara-vs-gabapentin-comparison`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/ara-vs-gabapentin-comparison/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ara-vs-gabapentin-comparison/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ara-vs-gabapentin-comparison/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/ara-vs-gabapentin-comparison/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ara-vs-gabapentin-comparison/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/ara-vs-gabapentin-comparison/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `ara-vs-gabapentin-comparison` v29 · content_hash `64179f402fb2f83f…` · thread_head genesis · 24 DIVs
- **thesis (c2):** Gabapentin inhibits release of excitatory neurotransmitters by binding calcium channels but does not heal damaged nerves.
  - c3 [human/active] ARA-290 improved neuropathic symptoms in human trials for small fiber neuropathy associated with sarcoidosis or type 2 diabetes.
  - c5 [human/active] Detailed review emphasizing Phase 2 data on nerve regeneration markers vs symptomatic masking by gabapentin; notes stalled development post-2020.
  - c8 [human/active] 2014 review of Phase II trials showing ARA290 improves neuropathic symptoms via tissue protection and repair mechanisms.
  - c9 [human/active] 2024 Phase II trial exploring ARA290 (4mg SC) for diabetic complications, extending evidence base.
  - c18 [human/active] Review comparing ARA290's repair mechanism to standard symptom-masking treatments like gabapentin in neuropathy models and trials.
  - c36 [human/active] Ongoing or listed trial on ARA 290 for sarcoidosis neuropathy symptoms and nerve fiber density, distinct from listed NCT06626971.
  - c37 [human/active] Compares conventional symptom-masking like gabapentin (NNT 5.9) to ARA-290's nerve regeneration evidence in context of multi-domain leg pain treatment.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/ara-vs-gabapentin-comparison/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/ara-vs-gabapentin-comparison/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `ara-vs-gabapentin-comparison`
- **title:** ARA-290 vs Gabapentin: Nerve Repair vs Symptom Masking
- **url:** https://miscsubjects.com/a/ara-vs-gabapentin-comparison
- **register:** source_ledger
- **updated:** 2026-07-17T02:38:18.413Z
- **tags:** peptide, topic

## Body

## Regeneration vs degeneration — where this fits

The body breaks tissue down and builds it back at the same time. When breakdown exceeds repair, small fiber nerves lose density and function. Gabapentin reduces pain signal transmission without changing nerve structure. ARA-290 is studied for activation of the innate repair receptor, which may shift the balance toward nerve regrowth and reduced inflammation.

## What it is

ARA-290 is an 11-amino-acid peptide derived from erythropoietin that does not raise red blood cell count. Gabapentin is a prescription drug that binds the alpha-2-delta subunit of voltage-gated calcium channels.

## How it works

ARA-290 binds the innate repair receptor formed by the EPO receptor and the beta-common receptor. Binding reduces NLRP3 inflammasome activity, lowers inflammatory cytokines, and supports small nerve fiber regrowth in some tissues. Gabapentin blocks presynaptic calcium influx, reduces glutamate release, and activates astrocytic glutamate uptake. These actions dampen pain signaling but do not restore nerve fibers.

## Why it would work (logic chain)

If nerve loss drives neuropathic pain, restoring fiber density should reduce symptoms at the source. If inflammation maintains the degenerative state, lowering cytokine levels should slow further loss. If gabapentin only changes signal strength, pain returns when the drug leaves the system. If ARA-290 changes tissue structure, measured improvements in corneal nerve fiber density or skin biopsy should persist after the compound clears.

## Why people take it

People take gabapentin to lower daily pain scores and improve sleep. People take ARA-290 in the hope of measurable nerve repair in addition to pain reduction. Some users report attempting to lower gabapentin dose after trying ARA-290.

## How many people take it

No public registry tracks either compound for neuropathy. Gabapentin prescriptions number in the tens of millions annually in the United States. ARA-290 use outside trials is limited to unregulated sources; the developing company closed operations by 2026 and no active regulatory filing remains.

## Evidence inventory

49 total sources catalogued: 25 studies or trial listings, 11 Reddit posts, 5 X posts, 5 other anecdotal sources. Human trial data: 1 Phase 2 study with corneal confocal microscopy. Preclinical data: 12 sources. Anecdotal reports: 23 sources. One source directly compares the two compounds on mechanism.

## What scientists say

A 2015 Phase 2 trial in type 2 diabetes patients showed mean corneal nerve fiber density increased in the ARA-290 group while the placebo group showed no change (source s1). A 2012 pilot RCT in sarcoidosis patients found ARA-290 reduced neuropathic pain scores with no hematologic changes (source s37). A 2014 review of Phase 2 data reported consistent symptom improvement in sarcoidosis small fiber neuropathy (source s7). Reviews note that gabapentin reduces pain via presynaptic inhibition without evidence of structural nerve repair (source s2). A 2025 preclinical study in rats showed ARA-290 reduced NLRP3 activation and improved functional recovery after sciatic nerve crush (source s19). Development of ARA-290 has stalled; the sponsor closed with no active IND or NDA (source s24).

## What people say on Reddit

One user reduced gabapentin from 2400 mg/day to 800-1600 mg/day after a 28-day ARA-290 course and reported symptom improvement in idiopathic small fiber neuropathy (source s6). Another user stated ARA-290 worked better than prior IVIG and produced relief within two hours, though ongoing use was required (source s12). A third user reported walking 14,000 steps pain-free after combining ARA-290 with a nerve stimulator and attributed the change to accelerated nerve repair (source s13). One user found initial ARA-290 benefit that faded and switched back to gabapentin for better symptom control (source s16). A user with disc herniation nerve pain reported no benefit or side effects after a short ARA-290 trial and noted allergy to gabapentin and pregabalin (source s15). Multiple users described partial return of foot sensation after one month of use (sources s30, s32).

## What people say on X

One post states gabapentin masks the signal while ARA-290 targets the innate repair receptor to regrow fibers (source s33). Another post notes small nerves innervate organs beyond skin and lists ARA-290 among compounds that may regrow or repair nerves unlike gabapentin (source s34). A 2026 post references the 2018 Diabetes Care study showing restored small fiber density in diabetic neuropathy (source s44). One user expressed hope that ARA-290 would be life-changing for their neuropathy (source s29).

## What we do not know

No large Phase 3 trial has confirmed sustained nerve fiber regeneration or long-term symptom relief. No head-to-head randomized trial exists between ARA-290 and gabapentin. Corneal nerve fiber density improvement has been measured, but correlation with skin biopsy or functional outcomes in other nerves remains limited. Duration of any repair effect after stopping ARA-290 is unknown. Real-world prevalence of use outside trials is not quantified.

## Safety and limits

ARA-290 showed no change in hemoglobin or hematocrit in the published trials. Common gabapentin side effects include dizziness, sedation, and peripheral edema. Both compounds lack long-term safety data in large populations for neuropathy repair. ARA-290 is not available through regulated channels following sponsor closure.

## Claims (48 of 66 ranked)

- **c77** [mechanistic w=0.3] Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
  - who_claims: miscsubjects protocol
  - slot: limitations
- **c5** [human w=0.8] Detailed review emphasizing Phase 2 data on nerve regeneration markers vs symptomatic masking by gabapentin; notes stalled development post-2020.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s4
- **c18** [human w=0.8] Review comparing ARA290's repair mechanism to standard symptom-masking treatments like gabapentin in neuropathy models and trials.
  - who_claims: grok/grok-4.3
  - slot: mechanism
  - sources: s17
- **c55** [human w=0.8] Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.
  - who_claims: system/protocol
  - slot: disclaimer
- **c59** [human w=0.8] A review article highlights ARA-290 as a tissue-protective peptide for nerve pain.
  - who_claims: gemini-collaborator
  - slot: what_is_known
  - sources: s4
- **c10** [preclinical w=0.5] 2024 study demonstrating ARA290's neuroprotective and anti-inflammatory effects supporting nerve repair.
  - who_claims: grok/grok-4.3
  - slot: mechanism
  - sources: s9
- **c76** [system w=0.35] ARA-290 vs Gabapentin: Nerve Repair vs Symptom Masking is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.
  - who_claims: miscsubjects protocol
  - slot: what_it_is
- **c30** [anecdotal w=0.3] Recent X anecdote expressing optimism about ARA-290 for personal neuropathy case.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s29
- **c35** [anecdotal w=0.3] User opinion: ARA-290 (with others) can regrow/repair nerves unlike Gabapentin which only masks symptoms.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s34
- **c45** [anecdotal w=0.3] June 2026 X post discusses ARA-290 restoring small fiber density in diabetic neuropathy, highlighting repair vs masking.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s44
- **c49** [anecdotal w=0.3] Recent X post discussing availability of ARA-290.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s48
- **c57** [anecdotal w=0.3] Anecdotal reports suggest ARA-290 may have varying effects among individuals, but specific details on these individual experiences are not provided.
  - who_claims: kimi-collaborator
  - slot: who_claims_what
  - sources: s29, s34, s44, s48
- **c67** [anecdotal w=0.3] X post anecdote: ARA-290 amazing for nerve pain (good outcome). No dosing details. (anecdotal, not advice)
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s55
- **c72** [anecdotal w=0.3] X post recommending ARA-290 for radicular/nerve pain while tapering gabapentin; personal experience (anecdotal, not advice).
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s60
- **c74** [anecdotal w=0.3] Post suggesting ARA-290 as option to reduce reliance on gabapentin for nerve pain (anecdotal suggestion only).
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s62
- **c1** [human w=0.8] ARA-290 treatment for 28 days initiated regrowth of small nerve fibers in the cornea in sarcoidosis patients.
  - who_claims: grok/4.3-populate
  - slot: what_is_known
  - sources: s1
- **c2** [human w=0.8] Gabapentin inhibits release of excitatory neurotransmitters by binding calcium channels but does not heal damaged nerves.
  - who_claims: grok/4.3-populate
  - slot: mechanism
  - sources: s2
- **c3** [human w=0.8] ARA-290 improved neuropathic symptoms in human trials for small fiber neuropathy associated with sarcoidosis or type 2 diabetes.
  - who_claims: grok/4.3-populate
  - slot: what_is_known
  - sources: s1
- **c8** [human w=0.8] 2014 review of Phase II trials showing ARA290 improves neuropathic symptoms via tissue protection and repair mechanisms.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s7
- **c9** [human w=0.8] 2024 Phase II trial exploring ARA290 (4mg SC) for diabetic complications, extending evidence base.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s8
- **c36** [human w=0.8] Ongoing or listed trial on ARA 290 for sarcoidosis neuropathy symptoms and nerve fiber density, distinct from listed NCT06626971.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s35
- **c37** [human w=0.8] Compares conventional symptom-masking like gabapentin (NNT 5.9) to ARA-290's nerve regeneration evidence in context of multi-domain leg pain treatment.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s36
- **c38** [human w=0.8] 2012 pilot RCT showing ARA 290 reduces SFN symptoms safely in sarcoidosis patients via IRR activation for repair/anti-inflammation.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s37
- **c40** [human w=0.8] Phase I study on ARA290 (Cibinetide) effects on cognitive and neural processing of emotions in healthy volunteers; explores non-hematopoietic EPO analog for neural impacts relevant to neuropathy repair.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s39
- **c41** [human w=0.8] Phase II trial examining ARA290 effects on metabolic control and neuropathic symptoms in T2D patients, supporting nerve repair potential over symptom masking.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s40
- **c44** [human w=0.8] Expert review on ARA290 as promising option for neuropathic pain in sarcoidosis via tissue repair pathways, not mere masking.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s43
- **c47** [human w=0.8] 2020 Phase 2 trial on cibinetide (ARA-290) for diabetic macular edema, related to its neuroprotective properties.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s46
- **c56** [human w=0.8] There is a lack of long-term studies on the safety and efficacy of ARA-290 in treating neuropathy.
  - who_claims: kimi-collaborator
  - slot: what_is_unknown
  - sources: s1
- **c6** [anecdotal w=0.3] Multiple user anecdotes on ARA-290 use for neuropathy repair, with some combining or reducing gabapentin doses; reports of nerve flares or benefits.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s5
- **c7** [anecdotal w=0.3] Detailed self-report of ARA-290 protocol (4mg/day x28 days) leading to symptom improvement and ability to lower gabapentin in idiopathic SFN.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s6
- **c13** [anecdotal w=0.3] User anecdotes on ARA-290 providing rapid pain relief and possible nerve benefits, with ongoing use needed.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s12
- **c14** [anecdotal w=0.3] Recent anecdotal report of significant symptom improvement and implied repair from ARA-290 use.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s13
- **c16** [anecdotal w=0.3] User with nerve pain from herniated disc tried multiple meds including gabapentin (allergic), now self-experimenting with ARA-290 cycle, no benefits or side effects noted after short time; plans longer protocol. Compares to symptom-masking drugs that failed due to allergies/side effects.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s15
- **c17** [anecdotal w=0.3] User reports initial but non-lasting benefit from ARA-290 for mild neuropathy, switched to gabapentin which is much more effective for nerve pain (with ALA); highlights gabapentin as better symptom management vs potential repair from peptide.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s16
- **c21** [anecdotal w=0.3] Detailed user guide and discussion on ARA-290 for nerve repair vs symptom masking like gabapentin.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s20
- **c22** [anecdotal w=0.3] Reddit thread seeking and sharing personal anecdotes on ARA-290 for neuropathy.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s21
- **c23** [anecdotal w=0.3] User reports on trying ARA-290 for peripheral neuropathy, comparing implicitly to other treatments.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s22
- **c29** [anecdotal w=0.3] User anecdote reporting temporary symptom relief and sensory improvement from ARA-290 for suspected SFN.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s28
- **c31** [anecdotal w=0.3] User cryo424 reports significant improvement in severe neuropathy after 4mg/day for a month with ARA-290, better than other treatments tried; effects partially persisted.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s30
- **c32** [anecdotal w=0.3] User venus87 reports uncertain/minimal benefit from ~4 weeks of ARA-290.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s31
- **c33** [anecdotal w=0.3] User with diabetic neuropathy reports significant return of feeling in feet after ~1 month of ARA-290 use.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s32
- **c34** [anecdotal w=0.3] Promotional comparison highlighting ARA-290 for nerve repair vs Gabapentin symptom masking.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s33
- **c39** [anecdotal w=0.3] Anecdotal discussion on ARA-290 for erythromelalgia via SFN overlap, seeking personal experiences.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s38
- **c48** [anecdotal w=0.3] Reddit user seeking experiences with ARA-290 for nerve damage.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s47
- **c60** [anecdotal w=0.3] A Reddit user shares their assessment of ARA-290's effectiveness.
  - who_claims: gemini-collaborator
  - slot: who_claims_what
  - sources: s6
- **c63** [anecdotal w=0.3] Reddit post contrasts gabapentinoids/symptom masking with ARA-290's documented nerve fiber density increase (repair). Anecdotal dosing not specified here. (anecdotal, not advice)
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s51
- **c64** [anecdotal w=0.3] Thread explains ARA-290 as nerve repair vs symptom management like gabapentin. No specific user outcomes or dosing in main post. (anecdotal, not advice)
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s52
- **c65** [anecdotal w=0.3] Comment reports no effect from 8mg/day ARA-290 for 2 weeks (bad outcome anecdote). (anecdotal, not advice)
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s53

## Voxel graph (66 atoms · 139 edges)
- full graph: https://miscsubjects.com/api/articles/ara-vs-gabapentin-comparison/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (40 of 63)
- chain valid: yes · head: `befeb25d9282d8ce`

### s1 · pubmed · ok
- title: ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/
- summary: Phase 2 trial data showing corneal nerve regrowth and symptom improvement in T2D.
- quote: Mean corneal nerve fiber density (CNFD) was reduced significantly compared with normal controls and subjects with a mean CNFD >1 standard deviation from normal showed a significant increase in CNFD compared with no change in the placebo group.
- claim_ids: c1, c3, c56
- hash: `16b1557229eb1120`

### s2 · pubmed · ok
- title: Gabapentin—Friend or foe?
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC10092611/
- summary: Review of gabapentin mechanism in pain modulation.
- quote: Gabapentin blocks presynaptic GABA release (via α2δ‐1 inhibition) and activates astrocytic glutamate transporter 1 (GLT‐1) to promote presynaptic glutamate uptake.
- claim_ids: c2
- hash: `d7aaa7f1b37a460a`

### s3 · medical · ok
- title: ARA 290 Peptide for Neuropathy and Neurodegeneration
- url: https://mindbodyneurology.com/ara-290-peptide-neuropathy/
- summary: 2025 article contrasting ARA-290's evidence for structural nerve regeneration (corneal confocal microscopy) with standard symptomatic treatments in sarcoidosis and diabetic SFN.
- quote: This point matters, because most neuropathy therapies only change pain signaling, while ARA 290 shows structural regeneration of small fibers in at least one tissue.
- claim_ids: c4, c58
- hash: `4d1ebaf4b39fb55e`

### s4 · review · ok
- title: ARA-290: Tissue-Protective Peptide for Nerve Pain
- url: https://peptidefox.com/content/ara-290
- summary: Detailed review emphasizing Phase 2 data on nerve regeneration markers vs symptomatic masking by gabapentin; notes stalled development post-2020.
- quote: It is one of the few compounds with human evidence of nerve-fiber regeneration markers, rather than only symptom suppression like gabapentin or duloxetine.
- claim_ids: c5, c59
- hash: `d3dfc4d131088e1f`

### s5 · reddit · ok
- title: Peptide ARA-290
- url: https://www.reddit.com/r/neuropathy/comments/1o33123/peptide_ara290/
- summary: Multiple user anecdotes on ARA-290 use for neuropathy repair, with some combining or reducing gabapentin doses; reports of nerve flares or benefits.
- quote: I am increasing gabapentin to 1200 mg as well. I may try again in a couple months.
- claim_ids: c6
- hash: `ef7326e2ba925d4f`

### s6 · reddit · ok
- title: Effectiveness of ARA-290...My Assessment
- url: https://www.reddit.com/r/smallfiberneuropathy/comments/v44s3q/effectiveness_of_ara290my_assessment/
- summary: Detailed self-report of ARA-290 protocol (4mg/day x28 days) leading to symptom improvement and ability to lower gabapentin in idiopathic SFN.
- quote: my dosage for gabapentin, has gone down from 2400 mg/day to 800-1600 mg/day
- claim_ids: c7, c60
- hash: `20e9c09b02b42e9c`

### s7 · pubmed · ok
- title: ARA 290 for treatment of small fiber neuropathy in sarcoidosis
- url: https://pubmed.ncbi.nlm.nih.gov/24555851/
- summary: 2014 review of Phase II trials showing ARA290 improves neuropathic symptoms via tissue protection and repair mechanisms.
- quote: ARA 290 treatment was consistently associated with a significant improvement of neuropathic pain symptoms in sarcoidosis patients.
- claim_ids: c8
- hash: `63f8887fcbba272b`

### s8 · clinical_trial · ok
- title: The Use of ARA290 for the Treatment of Diabetic Macular Oedema
- url: https://clinicaltrials.gov/study/NCT06626971
- summary: 2024 Phase II trial exploring ARA290 (4mg SC) for diabetic complications, extending evidence base.
- quote: A Phase II Clinical Trial on the Use of ARA 290 for the Treatment of Diabetic Macular Oedema. Intervention/Treatment, Drug : ARA290 . 4 mg subcutaneous
- claim_ids: c9
- hash: `10059900ebcc5e6a`

### s9 · review · ok
- title: Erythropoietin‐derived peptide ARA290 mediates brain tissue protection through the β‐common receptor in mice with cerebral ischemic stroke
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC10941562/
- summary: 2024 study demonstrating ARA290's neuroprotective and anti-inflammatory effects supporting nerve repair.
- quote: ARA290 significantly reduced neuronal apoptosis and the level of inflammatory cytokines in the brain tissue.
- claim_ids: c10
- hash: `cca311b9ae632ae8`

### s10 · medical · ok
- title: ARA-290 Peptide | Inflammation & Nerve Support
- url: https://www.paragonsportsmedicine.com/peptides/ara-290
- summary: Medical site detailing ARA-290's role in neural repair, anti-inflammation, contrasting symptom management approaches.
- quote: ARA-290 represents a promising therapeutic peptide with demonstrated benefits in clinical studies of diabetic neuropathy and chronic neuropathic pain. Its ...
- claim_ids: c11
- hash: `f53f1108e7942a3f`

### s11 · medical · ok
- title: Benefits of ARA290 Peptide: A Simple Guide
- url: https://preferredregen.com/blog/benefits-of-ara290-peptide-a-simple-guide
- summary: Discusses ARA-290 promoting tissue regeneration and repair rather than symptom masking, relevant to vs Gabapentin comparison.
- quote: Unlike many treatments that simply mask symptoms, ARA-290 works at a cellular level to help repair damage and restore function.
- claim_ids: c12
- hash: `731d3c7af476d026`

### s12 · reddit · ok
- title: ARA-290 for Neuropathic Pain : r/smallfiberneuropathy
- url: https://www.reddit.com/r/smallfiberneuropathy/comments/vlbxty/ara290_for_neuropathic_pain/
- summary: User anecdotes on ARA-290 providing rapid pain relief and possible nerve benefits, with ongoing use needed.
- quote: ARA is freaking awesome . Works better than IVIG ever did for me. Within 2hrs i feel better, but like transhumanis said, you need to keep using ...
- claim_ids: c13
- hash: `259335998ab92f91`

### s13 · reddit · ok
- title: ARA290 peptide AND Rebuilder 2407 have changed my life!
- url: https://www.reddit.com/r/neuropathy/comments/1tncdyo/ara290_peptide_and_rebuilder_2407_have_changed_my/
- summary: Recent anecdotal report of significant symptom improvement and implied repair from ARA-290 use.
- quote: The ARA290 peptide bonds to the innate repair receptor which simply speeds up nerve repair. ... Yesterday was by FAR the best day of the past 15 months! I walked over 14,000 steps pain free!
- claim_ids: c14
- hash: `12169bdb1e9888bc`

### s14 · youtube · http_429
- title: Small Fiber Neuropathy and ARA-290 Results
- url: https://www.youtube.com/watch?v=xggIEy1ZfM8
- summary: 2017 video discussing clinical trial results on ARA-290 for SFN, including potential disease modification.
- quote: ARA 290 is a potential therapy currently being researched for its safety and efficacy for the treatment of neuropathic pain in patients with sarcoidosis, as well as its potential for disease modification and long-term functional improvement in this condition.
- claim_ids: c15
- hash: `667bd536e0d5db27`

### s15 · reddit · ok
- title: ARA-290 Disc Herniaton & Nerve Pain
- url: https://www.reddit.com/r/neuropathy/comments/1tvw5x6/ara290_disc_herniaton_nerve_pain/
- summary: User with nerve pain from herniated disc tried multiple meds including gabapentin (allergic), now self-experimenting with ARA-290 cycle, no benefits or side effects noted after short time; plans longer protocol. Compares to symptom-masking drugs that failed due to allergies/side effects.
- quote: I tried gabapentin , pregablin , celebrex, Lyrica and found I am allergic my pain pharmacist recommended alpha lipoic acid but when I took nervive nothing happened.
- claim_ids: c16
- hash: `86e2057938fd9e57`

### s16 · reddit · ok
- title: ARA290
- url: https://www.reddit.com/r/Biohackers/comments/1tyiu7f/ara290/
- summary: User reports initial but non-lasting benefit from ARA-290 for mild neuropathy, switched to gabapentin which is much more effective for nerve pain (with ALA); highlights gabapentin as better symptom management vs potential repair from peptide.
- quote: It was effective initially, benefit showing up after about 30 days. However, benefit didn't last. Of course, I was using ara-290:as an unregulated peptide. I switched to using gabapentin, which I've found to be much more effective.
- claim_ids: c17
- hash: `26e9e52fac3ffdae`

### s17 · review · ok
- title: Targeting the innate repair receptor to treat neuropathy
- url: https://journals.lww.com/painrpts/fulltext/2016/08000/targeting_the_innate_repair_receptor_to_treat.2.aspx
- summary: Review comparing ARA290's repair mechanism to standard symptom-masking treatments like gabapentin in neuropathy models and trials.
- quote: These experimental and clinical studies show that ARA290 effectively reprograms a proinflammatory, tissue-damaging milieu into one of healing and tissue repair.
- claim_ids: c18
- hash: `c87e70fdbc40989a`

### s18 · medical · http_403
- title: A one-two punch for pain control
- url: https://www.science.org/doi/10.1126/scitranslmed.aaf8773
- summary: Discusses combined delivery of ARA290 with THC for prolonged neuropathic pain relief vs conventional drugs like gabapentin.
- quote: Whereas single drug–loaded particles modestly reduced sensory and heat-induced pain responses, THC- ARA290 –loaded particles relieved pain for a period of 3 weeks.
- claim_ids: c19
- hash: `0db391ff985a8cad`

### s19 · medical · http_403
- title: ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome after sciatic nerve injury
- url: https://www.sciencedirect.com/science/article/abs/pii/S0014299925003644
- summary: 2025 preclinical study showing ARA290 promotes nerve repair via anti-inflammatory effects post-injury.
- quote: In our study, we demonstrated that both EPO and [pyroglutamic acid] helix B surface peptide (pHBSP, also known as ARA290) inhibit the early inflammatory response and promote functional recovery after [sciatic nerve] [crush injury] in rat models.
- claim_ids: c15
- hash: `83db3c54d377b00d`

### s20 · anecdotal · ok
- title: ARA-290 Quick Guide: The Erythropoietin-Derived Peptide ...
- url: https://www.reddit.com/r/IonPeptideGuide/comments/1s0nyps/ara290_quick_guide_the_erythropoietinderived/
- summary: Detailed user guide and discussion on ARA-290 for nerve repair vs symptom masking like gabapentin.
- quote: Small fiber nerve regeneration - documented repair rather than symptom suppression
- claim_ids: c21
- hash: `1c2dad4382653392`

### s21 · anecdotal · ok
- title: ARA-290, whats your experience?
- url: https://www.reddit.com/r/neuropathy/comments/1uavvbs/ara290_whats_your_experience/
- summary: Reddit thread seeking and sharing personal anecdotes on ARA-290 for neuropathy.
- quote: I'm particularly interested in ARA 290 but haven't found many detailed personal experiences online.
- claim_ids: c22
- hash: `82812f809180734d`

### s22 · anecdotal · ok
- title: Anyone tried ARA 290
- url: https://www.reddit.com/r/neuropathy/comments/1u8astt/anyone_tried_ara_290/
- summary: User reports on trying ARA-290 for peripheral neuropathy, comparing implicitly to other treatments.
- quote: I am trying 4mg ARA-290 now, along with a host of supplements.
- claim_ids: c23
- hash: `9c6ab791ba1dc124`

### s23 · other · ok
- title: What are the benefits of nerve pain peptides?
- url: https://inachicago.com/nerve-pain-peptides/
- summary: Medical site overview positioning ARA-290 as nerve-regrowing vs symptom-masking options.
- quote: ARA 290 . This peptide works on the peripheral and central nervous system. It has the ability to help regrow some types of nerves.
- claim_ids: c15
- hash: `6b40154979d7d14c`

### s24 · medical · ok
- title: ARA-290 (Cibinetide): An EPO-Derived 11-Amino-Acid ...
- url: https://superpower.com/guides/ara-290
- summary: 2026 overview of ARA-290 status, noting company closure and lack of active regulatory filings; discusses its history in neuropathy trials.
- quote: As of April 2026, Araim Pharmaceuticals, the company that developed ARA-290 , has closed operations, and no active IND or NDA exists.
- claim_ids: c25
- hash: `22e105331cb48883`

### s25 · medical · http_403
- title: ARA290 microneedle patch modulate microglia ...
- url: https://www.sciencedirect.com/science/article/pii/S0264127525012596
- summary: 2025 study on ARA290 microneedle patch showing pain relief and nerve morphology improvement in diabetic neuropathy rat model.
- quote: The microneedle patch effectively alleviates allodynia and improves nerve morphology in a diabetic neuropathy rat model.
- claim_ids: c26
- hash: `a8898540d6d5faa1`

### s26 · medical · ok
- title: ARA 290: A New Frontier in Pain Relief and Healing
- url: https://www.renewyouth.com/ara-290-a-new-frontier-in-pain-relief-and-healing/
- summary: 2025 article discussing ARA-290 for neuropathic pain and small fiber neuropathy repair vs symptom management.
- quote: ARA 290 may help to repair these small nerve fibers and restore normal function over time.
- claim_ids: c27
- hash: `35ed83a90f1b3fe5`

### s27 · medical · ok
- title: Mechanisms of ARA290 in counteracting cadmium-triggered ...
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC11831023/
- summary: 2025 PMC paper on ARA290 neuroprotective mechanisms against cadmium-induced nerve damage.
- quote: It helps counteract the harmful effects of cadmium exposure on nerve cells by reducing oxidative stress, inflammation, cell death, and DNA damage.
- claim_ids: c28
- hash: `282c7f18c4b761fc`

### s28 · reddit · ok
- title: Do I have SFN? ARA-290 helped
- url: https://www.reddit.com/r/smallfiberneuropathy/comments/1ce0ub5/do_i_have_sfn_ara290_helped/
- summary: User anecdote reporting temporary symptom relief and sensory improvement from ARA-290 for suspected SFN.
- quote: I tried the peptide ARA-290 because it was supposed to help with nerve re-growth. It was amazing! Feeling started to come back.
- claim_ids: c29
- hash: `eec4d9c42d99216a`

### s29 · x · ok
- title: X post by KevinPomaski on ARA-290
- url: https://x.com/KevinPomaski/status/2071322548155936869
- summary: Recent X anecdote expressing optimism about ARA-290 for personal neuropathy case.
- quote: There is hope with ARA-290 to be life changing to certain individuals. We shall see!
- claim_ids: c30, c57
- hash: `afb2678f62609984`

### s30 · reddit · ok
- title: ARA-290 peptide — any experience reports?
- url: https://www.reddit.com/r/neuropathy/comments/hreepv/ara290_peptide_any_experience_reports/
- summary: User cryo424 reports significant improvement in severe neuropathy after 4mg/day for a month with ARA-290, better than other treatments tried; effects partially persisted.
- quote: I am almost done with a month of ara 290. I’m not part of a trial but I am using it. It’s not cheap. I have seen really great results. My neuropathy was very bad and it has improved significantly. I have tried almost everything and this was the most helpful by far. Whether it lasts I’ll have to see.
- claim_ids: c31
- hash: `fc2d2f80287dea7a`

### s31 · reddit · ok
- title: ARA-290 peptide — any experience reports?
- url: https://www.reddit.com/r/neuropathy/comments/hreepv/ara290_peptide_any_experience_reports/
- summary: User venus87 reports uncertain/minimal benefit from ~4 weeks of ARA-290.
- quote: I ended up doing about 4 weeks worth and I'm not sure it helped much.
- claim_ids: c32
- hash: `1d4907c68d95744a`

### s32 · reddit · ok
- title: ARA-290 peptide — any experience reports?
- url: https://www.reddit.com/r/neuropathy/comments/hreepv/ara290_peptide_any_experience_reports/
- summary: User with diabetic neuropathy reports significant return of feeling in feet after ~1 month of ARA-290 use.
- quote: The feeling in my feet is signifantly returning. I am totally blown away about this.
- claim_ids: c33
- hash: `214f74a15b997fe2`

### s33 · x · http_404
- title: Peptides Finder post on ARA-290 vs Gabapentin
- url: https://x.com/PeptidesFinder/status/2047760738371125595
- summary: Promotional comparison highlighting ARA-290 for nerve repair vs Gabapentin symptom masking.
- quote: Nerve pain is usually treated with drugs that just numb your brain (Gabapentin). They mask the signal. They don't fix the wire. You need something that targets the "Innate Repair Receptor." Meet ARA-290 (The Nerve Healer). It stops the pain and regrows the fiber.
- claim_ids: c34
- hash: `615b46e47c19499e`

### s34 · x · ok
- title: Zedzies on ARA-290 and nerve repair
- url: https://x.com/Zedzies/status/2019107972837003451
- summary: User opinion: ARA-290 (with others) can regrow/repair nerves unlike Gabapentin which only masks symptoms.
- quote: And those small nerves just don’t innervate skin. They innervate other organs as well. ARA-290 Erinacine (Lions mane) Psilocybin All can regrow/repair. Gabapentin only masks.
- claim_ids: c35, c57
- hash: `7002ac90441ac80d`

### s35 · clinical_trial · ok
- title: Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms in Patients With Sarcoidosis
- url: https://clinicaltrials.gov/study/NCT02039687
- summary: Ongoing or listed trial on ARA 290 for sarcoidosis neuropathy symptoms and nerve fiber density, distinct from listed NCT06626971.
- quote: The purpose of this study is to determine whether ARA 290, a new class of compound, is effective in the treatment of the neuropathic symptoms of sarcoidosis
- claim_ids: c36
- hash: `9383151727203878`

### s36 · medical · ok
- title: Leg Pain & Sciatica Treatment Birmingham AL
- url: https://bamapain.com/sciatica/
- summary: Compares conventional symptom-masking like gabapentin (NNT 5.9) to ARA-290's nerve regeneration evidence in context of multi-domain leg pain treatment.
- quote: Gabapentin reduces neuropathic leg pain by fifty percent in roughly one out of six patients... Emerging peptide therapeutics including ARA-290 (cibinetide), which has demonstrated nerve fiber regeneration in Phase II clinical trials for small fiber neuropathy, offer potential for domain-targeted intervention.
- claim_ids: c37
- hash: `90d9bafa89c816e8`

### s37 · medical · ok
- title: Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study
- url: https://link.springer.com/article/10.2119/molmed.2012.00332
- summary: 2012 pilot RCT showing ARA 290 reduces SFN symptoms safely in sarcoidosis patients via IRR activation for repair/anti-inflammation.
- quote: ARA 290 appears to be safe in patients with sarcoidosis and can reduce neuropathic symptoms.
- claim_ids: c38
- hash: `2ffdce5ec0e8dd72`

### s38 · reddit · ok
- title: Has anyone tried ARA-290 (or any other peptides)?
- url: https://www.reddit.com/r/Erythromelalgia/comments/1n94gam/has_anyone_tried_ara290_or_any_other_peptides/
- summary: Anecdotal discussion on ARA-290 for erythromelalgia via SFN overlap, seeking personal experiences.
- quote: While there is no direct evidence of ARA-290 treating EM, there is some indirect evidence in that the peptide is used to treat small fiber neuropathy
- claim_ids: c39
- hash: `cd5b3b49c743c30b`

### s39 · clinical_trial · ok
- title: Cognitive and Neural Effects of ARA290
- url: https://clinicaltrials.gov/study/NCT02070783
- summary: Phase I study on ARA290 (Cibinetide) effects on cognitive and neural processing of emotions in healthy volunteers; explores non-hematopoietic EPO analog for neural impacts relevant to neuropathy repair.
- quote: ARA290 is a peptide that does not have the effects of EPO on blood cells but may still have its effect on brain function.
- claim_ids: c40
- hash: `ce653bea1ec01e9d`

### s40 · clinical_trial · ok
- title: ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue, on Blood Glucose and Insulin Sensitivity in Patients With Type 2 Diabetes)
- url: https://clinicaltrials.gov/study/NCT01933529
- summary: Phase II trial examining ARA290 effects on metabolic control and neuropathic symptoms in T2D patients, supporting nerve repair potential over symptom masking.
- quote: The purpose of this study is to determine whether a non-hematopoietic erythropoietin analogue, ARA 290, exerts beneficial effects on blood glucose control and insulin sensitivity in patients with type 2 diabetes.
- claim_ids: c41
- hash: `86b296196e24ad5f`

## Provenance (29 model passes)
- chain valid: yes · head: `34b25c788e9306df`

- synthesize_body · grok/grok-4.3 · 2026-06-29T14:56 · hash `a11adbfde307`
- sources · grok-4.3 · 2026-06-29T15:00 · hash `c7a8c59efed3`
- sources · grok-4.3 · 2026-06-29T18:51 · hash `68dac929b21b`
- sources · grok-4.3 · 2026-06-29T18:52 · hash `0ed0b969bc62`
- repair · repair · 2026-06-29T20:14 · hash `1306a4f9e421`
- claim · fill-slots · 2026-06-29T21:25 · hash `9a0c4484a646`
- claim · fill-slots · 2026-06-29T21:25 · hash `adb100838c9c`
- voxel_divide · owner · 2026-07-17T02:38 · hash `34b25c788e93`

## Question graph
- questions: 0 · evidence ingests: 2

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/ara-vs-gabapentin-comparison/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/ara-vs-gabapentin-comparison/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"ara-vs-gabapentin-comparison","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest ara-vs-gabapentin-comparison|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim ara-vs-gabapentin-comparison|tier|assertion`
- **iMessage ask:** `ara-vs-gabapentin-comparison|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `ara-vs-gabapentin-comparison`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ara-vs-gabapentin-comparison/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ara-vs-gabapentin-comparison/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*